Main Catalog

Found 92
Sort by
AMCP Annual Meeting
Member Free
Non-Member $30.00

Real-World Experience Managing Orphan Drugs Across Pharmacy and Medical Benefits

Contact Hours: 1.25. Recently approved drugs for orphan diseases have annual costs ranging from $90,000 to over $1 million, while also having variable value propositions.
Orphan Disease
AMCP Annual Meeting
Member Free
Non-Member $30.00

Patient Review and Restriction Programs: Prescription Drug Monitoring Programs and the Need for Collaboration

Contact Hours: 1.25. Patient Review and Restriction (PRR) programs are commonly used by health plans in doctor’s offices to manage the excessive prescribing of controlled substances or services.
Hospital/Health Systems
AMCP Annual Meeting
Member Free
Non-Member $30.00

More than Meets the Eye–Value-Based Contracts are More Prevalent than We Think

Contact Hours: 1.25. As the U.S. health care system evolves from a volume-driven system to one that rewards value, there is growing interest in value-based payment arrangements.
Value-Based Contracting
Nexus Conferences
Member Free
Non-Member $30.00

Medical Oncology Drug Cost Trends and Innovative, Practical Payer Management Strategies - Nexus 2018

Contact Hours: 1.5. Medical oncology drugs represent 35 to 47% percent of total medical benefit drug spend.
Oncology
AMCP Annual Meeting
Member Free
Non-Member $30.00

Key Forces Driving Change in Oncology

Contact Hours: 1.25. Oncology practice is changing rapidly as new advances in innovation lead to new evidence and testing requirements, as well as treatment guidelines.
Oncology
Nexus Conferences
Member Free
Non-Member $30.00

Federal and State Legislative and Regulatory Update - Nexus 2018

Contact Hours: 1.5. This must-attend session will bring you timely updates on the latest federal and state legislative and regulatory actions of interest to managed care and specialty pharmacy professionals.
Law
AMCP Annual Meeting
Member Free
Non-Member $30.00

Federal and State Legislative and Regulatory Update - Annual Meeting 2018

Contact Hours: 1.25. This must-attend session will bring you timely updates on the latest federal and state legislative and regulatory actions of interest to pharmacists and other managed care and specialty pharmacy professionals.
Law
Nexus Conferences
Member Free
Non-Member $30.00

Experience and Lessons Learned in Biosimilar Uptake - Nexus 2018

Contact Hours: 1.5. Although biosimilars have been on the market for some time, payers continue to face many challenges in implementation.
Biosimilars
Nexus Conferences
Member Free
Non-Member $30.00

Biosimilars in the United States: Barriers, Solutions, Real-World Evidence, and the Experience of One Health System

Contact Hours: 1.5. As of July 2019, the U.S. Food and Drug Administration (FDA) had approved 25 biosimilar or follow-on biologic products.
Biosimilars
AMCP Annual Meeting
Member Free
Non-Member $30.00

Best Practices to Implementing Proactive Communications Between Manufacturers and Payers

Contact Hours: 1.25. The recent enactment of the 21st Century Cures Act, and specifically Section 3037 (Cures 3037), modernized provisions of the Food and Drug Administration Modernization Act of 1997, Section 114 (FDAMA 114).
Managed Care Regulation